Is CureVac NV overvalued or undervalued?

As of 24 October 2025, the valuation grade for CureVac NV has moved from attractive to very attractive. The company appears to be undervalued, supported by a P/E ratio of 5, an EV to EBITDA ratio of 1.90, and an impressive PEG ratio of 0.03. In comparison with peers, PTC Therapeutics, Inc. has a P/E of 5.85 and an EV to EBITDA of 3.17, while Harmony Biosciences Holdings, Inc. shows a P/E of 11.40 and an EV to EBITDA of 6.94, indicating that CureVac NV is trading at a significant discount relative to its industry peers.
CureVac NV has delivered a year-to-date return of 57.18%, significantly outperforming the S&P 500's return of 15.47%, which reinforces the notion that the stock is undervalued given its strong performance metrics and favorable valuation ratios.